Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau
Clicks: 118
ID: 114359
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
118 views
28 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #347 of 438 articles by views in acta neuropathologica
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 438 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
In Alzheimer’s disease (AD) and other tauopathies, the cytosolic protein Tau misfolds and forms intracellular aggregates which accumulate within the brain leading to neurodegeneration. Clinical progression is tightly linked to the progressive spread of Tau pathology throughout the brain, and several lines of evidence suggest that Tau aggregates or “seeds” may propagate pathology by spreading from cell to cell in a “prion like” manner. Accordingly, blocking the spread of extracellular seeds with an antibody could be a viable therapeutic approach. However, as the structure of Tau seeds is unknown, it is only possible to rationally design therapeutic Tau antibodies by making a priori assumptions. To avoid this, we developed a robust and quantitative cell based assay and employed an unbiased screening approach to identify the antibody with the highest activity against human Tau seeds. The selected antibody (D), directed to the mid-region of Tau (amino acids 235–250), potently blocked the seeding of human AD Tau and was also fully efficacious against seeds from progressive supranuclear palsy. When we compared this antibody with previously described reference antibodies, we were surprised to find that none of these antibodies showed comparable efficacy against human pathological seeds. Our data highlight the difficulty of predicting antibody accessible epitopes on pathological Tau seeds and question the potential efficacy of some of the Tau antibodies that are currently in clinical development.
| Reference Key |
courade2018actaepitope
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jean-Philippe Courade;Rachel Angers;Georges Mairet-Coello;Nathalie Pacico;Kerry Tyson;Daniel Lightwood;Rebecca Munro;David McMillan;Robert Griffin;Terry Baker;Dale Starkie;Ruodan Nan;Marta Westwood;Marie-Laetitia Mushikiwabo;Sophie Jung;Geofrey Odede;Berni Sweeney;Andrew Popplewell;Gillian Burgess;Patrick Downey;Martin Citron;Jean-Philippe Courade;Rachel Angers;Georges Mairet-Coello;Nathalie Pacico;Kerry Tyson;Daniel Lightwood;Rebecca Munro;David McMillan;Robert Griffin;Terry Baker;Dale Starkie;Ruodan Nan;Marta Westwood;Marie-Laetitia Mushikiwabo;Sophie Jung;Geofrey Odede;Berni Sweeney;Andrew Popplewell;Gillian Burgess;Patrick Downey;Martin Citron; |
| Journal | acta neuropathologica |
| Year | 2018 |
| DOI |
doi:10.1007/s00401-018-1911-2
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.